When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
LightPath Technologies
The Trade: LightPath Technologies, Inc. (NASDAQ:LPTH) Chief Financial Officer Albert Miranda acquired a total of 4000 shares at an average price of $2.20. To acquire these shares, it cost $8,800.00.
What’s Happening: The company recently announced it presented updated results for its DKN-01 plus tislelizumab which showed "compelling" activity in first-line patients with gastric, gastroesophageal junction cancer.
What LightPath Technologies Does: Leap Therapeutics is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells.
ServiceSource International
The Trade: ServiceSource International, Inc. (NASDAQ:SREV) 10% owner Edenbrook Capital Llc, Jonathan Brolin acquired a total of 11100 shares shares at an average price of $1.36. The insider spent $15,095.34 to buy those shares.
What’s Happening: ServiceSource, during July, reported a Q2loss of $0.01 per share.
What ServiceSource International Does: ServiceSource International is a provider of customer and revenue lifecycle management solutions.
Navidea Biopharmaceuticals
The Trade: Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) Director Malcolm G Witter acquired a total of 20000 shares at an average price of $1.60. To acquire these shares, it cost $31,952.00.
What’s Happening: Navidea Biopharmaceutical, last month, reported a Q2 loss of $0.09 per share.
What Navidea Biopharmaceuticals Does: Navidea Biopharmaceuticals is a biotechnology company specialized in precision medicine.
Avalo Therapeutics
The Trade: Avalo Therapeutics, Inc. (NASDAQ:AVTX) Director Armistice Capital Llc, Armistice Capital Master Fund Ltd, Steven Boyd acquired a total of 5700000 shares at an average price of $2.20. To acquire these shares, it cost $12,557,901.85.
What’s Happening: The company recently priced its 12.5 million share public offering of common stock at $2.20 per share.
What Avalo Therapeutics Does: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
